NYBC Ventures general partner Jay Mohr and managing director Meg Wood (NYBC Ventures)

New blood and cell ther­a­py-fo­cused ven­ture fund emerges with $50M and a Jen­nifer Doud­na spin­out in tow

A $50 mil­lion ven­ture fund ded­i­cat­ed to blood-re­lat­ed fields and cell ther­a­pies emerged Thurs­day af­ter spend­ing about a year build­ing out its ini­tial in­vest­ments in a hand­ful of star­tups, in­clud­ing a Jen­nifer Doud­na spin­out work­ing on new can­cer and au­toim­mune ther­a­peu­tics.

The 60-year-old New York Blood Cen­ter, a non­prof­it that de­liv­ers blood prod­ucts, trans­fu­sion med­i­cine ser­vices and blood re­search across 17 states, has cre­at­ed the NY­BC Ven­tures fund to back star­tups work­ing on be­nign hema­tol­ogy, in­fec­tious dis­eases, cell ther­a­pies, de­vices, trans­fu­sion med­i­cine and oth­er ar­eas.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.